Losartan in hospitalized patients with COVID-19 in North America: An individual participant data meta-analysis
Description
CONCLUSIONS: In this IPD meta-analysis of hospitalized COVID-19 patients, we found no convincing evidence for the benefit of losartan versus control treatment, but a higher rate of hypotension adverse events with losartan.
